When was Seqens founded?

Seqens was founded in 2003 and raised its 1st funding round 13 years after it was founded.

Where is Seqens located?

Seqens is headquartered in Ecully, France. It is registered at No.1-7&12-17,3 floor,Genesis Square,Plot no.15 Intl Biotech Park,MIDC Phase 2,RG IT BT, Park,Maan, Pune, Pune, Maharashtra, India, 411057.

How many employees does Seqens have?

As of Sep 30, 2026, the latest employee count at Seqens is 1280.

Is Seqens a funded company?

Seqens is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 2016.

When was the latest funding round of Seqens?

Seqens' latest funding was a $***** Series A round on Jul 2017, with participation from 1 investor.

Where does Seqens rank among its competitors?

Seqens ranks 20th amongst 393 active competitors, of which 15 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Almac Group, which secured $417K in Sep, 2022.

Who are the top competitors of Seqens?

Seqens' top competitors include Concord Biotech, Biophore and Almac Group. Among them, Almac Group secured the most recent funding round in September, 2022.

Seqens - 2026 Company Profile, Funding & Competitors

Company Details

Website: www.seqens.com/
Social
Registered Address: No.1-7&12-17,3 floor,Genesis Square,Plot no.15 Intl Biotech Park,MIDC Phase 2,RG IT BT, Park,Maan, Pune, Pune, Maharashtra, India, 411057

Key Metrics

Founded Year

2003

Location

Ecully, France

Stage

Acquired

Latest Funding Round

Series A, Jul 2017, $*****

Investors

Ardian & 5 more

Ranked

20^th among 393 active competitors

Employee Count

1,280 as on Sep 30, 2026

Investment & Acquisitions

CELLforCURE & 1 more

Similar Companies

Concord Biotech & 439 more

Exit Details

Acquired by SK Capital (Dec 17, 2021)

View Seqens' full profile

Seqens is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
MONOLOM INDIA PHARMA PRIVATE LIMITED CIN: U24303PN2017FTC188118 , India, Active	Oct 27, 2017	₹10 - ₹50 Cr (As on Mar 31, 2025)	44 (As on Sep 30, 2024)

Seqens got acquired by SK Capital on Dec 17, 2021.

Click here to take a look at Seqens's acquisition in detail

Seqens has raised funding over 3 rounds. Its first funding round was on Jun 2016. Its latest funding round was a Series A round on Jul 2017 for $*****. 1 investor participated in its latest round. Seqens has 6 institutional investors.

Here is the list of recent funding rounds of Seqens:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 2017	6229920	Series A	1618653	4161277	5820547	7513902
Jun 21, 2016	3292857	Series A	1510278	6172533	5200714	5924853
Jun 2016	1619596	Series A	2350359	2451012	1905915	Eurazeo

Access funding benchmarks and valuations. Sign up today!

View details of Seqens's funding rounds and investors

Seqens' employee count trend

Seqens has 1,280 employees as of Sep 26. Here is Seqens's employee count trend over the years:

Uncover Seqens' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Seqens include Concord Biotech, Biophore and Almac Group. Here is the list of Top 10 competitors of Seqens, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Concord Biotech 1984, Ahmedabad (India), Public	CDMO focused on manufacturing API	$11.3M	Quadria Capital, Helix Investments & 18 others	69/100
2nd	Biophore 2007, Hyderabad (India), Seed	Development and manufacturing of niche pharmaceutical products for the generic industry	$2.74M	Ontario & 6 others	62/100
3rd	Almac Group 2001, Craigavon (United Kingdom), Series D	CRAMS company offering preclinical development and CDMO services, also offering companion diagnostic development	$339M	Genomic Health, Gates & 4 others	57/100
4th	Jagsonpal 1964, Delhi (India), Public	Traditional company manufacturing bulk drugs and finished formulations	-	Convergent, Aresko	55/100
5th	Indoco Remedies 1947, Mumbai (India), Public	Provider of APIs manufacturing and formulation services	-	Baring Private Equity Partners	54/100
6th	Wanbury Limited 1990, Mumbai (India), Public	Manufacturer of anti-diabetic drugs	-	-	53/100
7th	Galenicum 2003, Barcelona (Spain), Late Stage	Turnkey solutions for drug development, manufacturing and regulatory approvals	-	Peninsula Capital	52/100
8th	Amino 1958, Frellstedt (Germany), Unfunded	CDMO focused on amino acids and small molecules	-	-	51/100
9th	Aizant 2005, Hyderabad (India), Series A	Company offering contract development services for small molecules	$7.59M	Zephyr Management, Zephyr Peacock & 39 others	50/100
10th	Asymchem 1995, Morrisville (United States), Public	CDMO providing comprehensive pharmaceutical development and manufacturing solutions globally	-	Hillhouse, CoStone Capital & 5 others	50/100
20th	Seqens 2003, Ecully (France), Acquired	Provider of contract manufacturing services for small molecules & peptides	-	Merieux Developement, Societe Generale Capital Partenaire ... & 4 others	48/100